• Citer

Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.

par Rohrberg, Kristoffer;Brandão, Mariana ;Castanon Alvarez, E.;Felip, Enriqueta;Gort, E.H.;Hiltermann, Jeroen Nicolaas;Izumi, H.;Kim, Dong-Wan;Kim, Sang We;Paz Ares, Luis;Solomon, B;Steinbusch, L.;Wauters, Els;Yoshida, T.;Chen, Huifang;Goldwin, Andrew;Jiang, Yu;Achour, Ikbel;Drachsler, Moritz Wolfgang;Cho, Byoung Chul
Référence Journal of clinical oncology, 41, 16_suppl, page (9050-9050)
Publication Publié, 2023-06

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.
Auteur:	Rohrberg, Kristoffer; Brandão, Mariana; Castanon Alvarez, E.; Felip, Enriqueta; Gort, E.H.; Hiltermann, Jeroen Nicolaas; Izumi, H.; Kim, Dong-Wan; Kim, Sang We; Paz Ares, Luis; Solomon, B; Steinbusch, L.; Wauters, Els; Yoshida, T.; Chen, Huifang; Goldwin, Andrew; Jiang, Yu; Achour, Ikbel; Drachsler, Moritz Wolfgang; Cho, Byoung Chul
Informations sur la publication:	Journal of clinical oncology, 41, 16_suppl, page (9050-9050)
Statut de publication:	Publié, 2023-06
Sujet CREF:	Cancérologie
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2023.41.16_suppl.9050